Provided by Tiger Trade Technology Pte. Ltd.

VBI Vaccines

0.0653
0.0000
Volume:- -
Turnover:2.15M
Market Cap:1.87M
PE:-0.02
High:0.0653
Open:0.0653
Low:0.0653
Close:0.0653
52wk High:1.35
52wk Low:0.0553
Shares:28.68M
Float Shares:26.73M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2957
EPS(LYR):-6.0261
ROE:-419.59%
ROA:-29.15%
PB:-0.34
PE(LYR):-0.01

Loading ...

Company Profile

Company Name:
VBI Vaccines
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.